HR Execs on the Move

AMAR INTERNATIONAL

www.amar-international.com

 
AMAR INTERNATIONAL is a Fairfax, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

United Medical Supply

United Medical Supply is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. United Medical Supply is based in Greensboro, NC. You can find more information on United Medical Supply at www.umedsupply.com

AdventHealth

AdventHealth is a faith-based, non-profit health care system headquartered in Altamonte Springs, Florida, that operates facilities within nine states across the United States.

Nova Ortho-Med

Nova Ortho-Med is a Carson, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Professional Medical Services

About J&K PMS, Inc., it's employees and company

Neuralstem

Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic